Molecular Pathology of Pancreatic Cancer: Implications for Molecular Targeting Therapy
Molecular Pathology of Pancreatic Cancer: Implications for Molecular Targeting Therapy
复制标题
DOI：
10.1016/j.cgh.2009.07.035
复制
发表时间：
2009-11-01
影响因子：
12.6
通讯作者：
Furukawa, Toru
中科院分区：
文献类型：
--
作者：
Furukawa, Toru
胰腺癌通过导管发育不良病变或胰腺上皮内瘤变（PanIN）发展。胰腺癌的起源仍有争议。胰腺癌的一些分子起源已被描述。例如，KRAS、SHH、CDKN 2A、TP53、SMAD 4和DUSP 6是胰腺癌发展和进展中的关键分子。了解致癌机制可以帮助研究人员找到胰腺癌的致命弱点。分子靶向是治疗这种毁灭性疾病的一种有前途的策略。
Pancreatic cancer develops through ductal dysplastic lesions or pancreatic intraepithelial neoplasia (PanIN). The origin of pancreatic cancer remains controversial. Some of the molecular origins of pancreatic cancer have been described. For example, KRAS, SHH, CDKN2A, TP53, SMAD4, and DUSP6 are crucial molecules in the development and progression of pancreatic cancer. Understanding the mechanisms of carcinogenesis could help researchers find the Achilles' heel of pancreatic cancer. Molecular targeting is a promising strategy for curing this devastating disease.